CN112601527B - 用于有效预防和治疗的选择性抗癌剂 - Google Patents

用于有效预防和治疗的选择性抗癌剂 Download PDF

Info

Publication number
CN112601527B
CN112601527B CN201980036058.2A CN201980036058A CN112601527B CN 112601527 B CN112601527 B CN 112601527B CN 201980036058 A CN201980036058 A CN 201980036058A CN 112601527 B CN112601527 B CN 112601527B
Authority
CN
China
Prior art keywords
cancer
compound
acid
piperdine
ethylflavopereirine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980036058.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112601527A (zh
Inventor
约翰·霍尔
西尔维·贝尔扬斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MOLECULAR INTERNATIONAL RESEARCH Inc
Original Assignee
MOLECULAR INTERNATIONAL RESEARCH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MOLECULAR INTERNATIONAL RESEARCH Inc filed Critical MOLECULAR INTERNATIONAL RESEARCH Inc
Publication of CN112601527A publication Critical patent/CN112601527A/zh
Application granted granted Critical
Publication of CN112601527B publication Critical patent/CN112601527B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980036058.2A 2018-03-31 2019-04-01 用于有效预防和治疗的选择性抗癌剂 Active CN112601527B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651133P 2018-03-31 2018-03-31
US62/651,133 2018-03-31
PCT/US2019/025234 WO2019191776A1 (en) 2018-03-31 2019-04-01 Selective anti-cancer agent effective for prevention and treatment

Publications (2)

Publication Number Publication Date
CN112601527A CN112601527A (zh) 2021-04-02
CN112601527B true CN112601527B (zh) 2024-12-31

Family

ID=66175524

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980036058.2A Active CN112601527B (zh) 2018-03-31 2019-04-01 用于有效预防和治疗的选择性抗癌剂

Country Status (5)

Country Link
US (1) US11083714B2 (https=)
EP (1) EP3773582B1 (https=)
JP (1) JP7491514B2 (https=)
CN (1) CN112601527B (https=)
WO (1) WO2019191776A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114224832A (zh) * 2022-02-11 2022-03-25 明度智云(浙江)科技有限公司 一种恩杂鲁胺注射剂及其制备方法和应用
WO2025068971A1 (en) * 2023-09-27 2025-04-03 Jina Pharmaceuticals Inc. Compositions containing cabazitaxel and lipids for oral administration
CN121466043A (zh) * 2026-01-09 2026-02-06 哈尔滨医科大学 香叶醇在制备胃癌化疗增敏剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059817A1 (fr) * 1981-03-11 1982-09-15 Mirko Beljanski Serpentine; alstonine et sempervirine, médicaments inhibant spécifiquement les cellules cancéreuses et tumorales

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415831A (en) 1965-07-16 1968-12-10 Smith Kline French Lab 2-isoquinolinyl(and carbolinyl) alkyloctahydroindolo [2,3-a]-quinolizines
US3468890A (en) 1966-06-09 1969-09-23 Sterling Drug Inc Pyrazino(1',2':1,2)pyrido(3,4-b)indoles
US3455936A (en) 1967-04-18 1969-07-15 Smithkline Corp Substituted indolo(2,3-a)quinolizinium salts
US3814773A (en) 1970-05-19 1974-06-04 American Home Prod Indole fused heterocyclic anti-inflammatory compounds
US3943148A (en) 1970-05-19 1976-03-09 American Home Products Corporation Indole fused heterocyclic diuretic compounds
HU169916B (https=) 1974-09-27 1977-02-28
FR2419725A1 (fr) 1978-03-13 1979-10-12 Beljanski Mirko Serpentine, alstonine et sempervirine, medicaments inhibant specifiquement les cellules cancereuses et tumorales
FR2450607A2 (fr) 1978-03-13 1980-10-03 Beljanski Mirko Composition pharmaceutique contenant comme principe actif la flavopereine
HU183234B (en) 1980-10-17 1984-04-28 Richter Gedeon Vegyeszet Process for the enantioselective synthesis of optically active cys-14-oxo-e-homo-eburnan
FR2639830B1 (fr) 1988-12-02 1991-03-22 Beljanski Mirko Composition antivirale et ses applications
FR2694693B1 (fr) 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
FR2751969B1 (fr) 1996-08-01 1998-12-04 Centre Nat Rech Scient Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
WO2002094270A2 (en) 2001-05-18 2002-11-28 Chemokine Therapeutics Corporation Mip-1 alpha receptor ligands - drugs for t-cell mediated and autoimmune diseases
EA008537B1 (ru) 2002-04-03 2007-06-29 Орион Корпорейшн Полициклические соединения как эффективные антагонисты альфа2-адренорецептора
JP4468638B2 (ja) 2003-01-31 2010-05-26 アリジェン製薬株式会社 インドール骨格を有するアルカロイドを含有するアスコフラノンの抗原虫作用増強剤およびこれらを含む抗原虫作用を有する薬剤組成物
JP4733058B2 (ja) 2004-02-18 2011-07-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造及びそのｄｐｐ−ｉｖインヒビターの形態での使用
US20090215853A1 (en) 2004-05-19 2009-08-27 Natural Source International Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
US20100256177A1 (en) * 2004-06-11 2010-10-07 Seshagiri Venkatachalam Flavopereirine derivatives for cancer therapy
JP2012097060A (ja) 2010-11-01 2012-05-24 Tottori Univ 新規ジヒドロキシベンゼン誘導体およびそれらを有効成分とする抗原虫剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059817A1 (fr) * 1981-03-11 1982-09-15 Mirko Beljanski Serpentine; alstonine et sempervirine, médicaments inhibant spécifiquement les cellules cancéreuses et tumorales

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Pan, Xiaohong等.Synthesis and Cytotoxicity of Sempervirine and Analogues.Journal of Organic Chemistry.2016,2194-2200. *
Synthesis and Cytotoxicity of Sempervirine and Analogues;Pan, Xiaohong等;Journal of Organic Chemistry;2194-2200 *
Targeting DNA with small molecules: a comparative study of a library of azonia aromatic chromophores;Rosa M.等;Organic & Biomolecular Chemistry;1-12 *
THE ANTICANCER AGENT PB-100 CONCENTRATES IN THE NUCLEUS AND NUCLEOLI OF HUMAN GLIOBLASTOMA CELLS BUT DOES NOT ENTER NORMAL ASTROCYTES;Beljanski, Mirko;International Journal of Oncology;81-85 *
The anticancer agent PB-100, selectively active on malignant cells, inhibits multiplication of sixteen malignant cell lines, even multidrug resistant;Beljanski, Mirko等;Genetics and Molecular Biology;29-33 *

Also Published As

Publication number Publication date
EP3773582B1 (en) 2023-10-25
US11083714B2 (en) 2021-08-10
US20210015803A1 (en) 2021-01-21
JP7491514B2 (ja) 2024-05-28
EP3773582A1 (en) 2021-02-17
EP3773582C0 (en) 2023-10-25
CN112601527A (zh) 2021-04-02
CA3094388A1 (en) 2019-10-03
WO2019191776A1 (en) 2019-10-03
JP2021528480A (ja) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7047148B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
WO2021183318A2 (en) Methods and compositions relating to improved combination therapies
KR20170045237A (ko) 항-pd1 또는 항-pdl1 단클론성 항체와 조합된 시티딘 유사체의 경구 제제를 사용한 질환 또는 장애를 치료하는 방법
AU2018215336A1 (en) Methods for treating cancer using HSP90 inhibitors
JP2018522021A (ja) 治療用化合物の脳への一方向送達のためのインプラント組成物
TW201700103A (zh) 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
CN112601527B (zh) 用于有效预防和治疗的选择性抗癌剂
WO2012128709A1 (en) A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
CN102772416A (zh) 包含GSK-3β抑制剂和SBE7-β-CD的药物组合物
EP4252774A1 (en) Combination therapy for treating pik3ca-mutated cancer
CN106029070A (zh) 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
JP7547360B2 (ja) Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
WO2008066783A2 (en) Therapeutic materials and methods
CA3094388C (en) Use of de-ethylflavopereirine as a selective anti-cancer agent
US20250275938A1 (en) Compositions and methods for treatment of cancer
CN101657098A (zh) 用于治疗造血性癌症和增殖性病症的固定药物比例
JP2025531278A (ja) 医薬組成物およびその使用
CN104114182A (zh) 罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用
CN113750096A (zh) 用于治疗外周t细胞淋巴瘤的喹啉衍生物
US20260115190A1 (en) Dispersions of etrumadenant
EP4587001A1 (en) Dispersions of etrumadenant
WO2020095184A1 (en) Combinations for treating cancer
HK40093376A (en) Combination therapy for treating pik3ca-mutated cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant